Tarsus Pharmaceuticals, Inc.TARSEarnings & Financial Report
Nasdaq
TARS Q3 2025 Key Financial Metrics
Revenue
$118.7M
Gross Profit
N/A
Operating Profit
$-14.5M
Net Profit
$-12.6M
Gross Margin
N/A
Operating Margin
-12.2%
Net Margin
-10.6%
YoY Growth
146.7%
EPS
$-0.30
Financial Flow
Tarsus Pharmaceuticals, Inc. Q3 2025 Financial Summary
Tarsus Pharmaceuticals, Inc. reported revenue of $118.7M for Q3 2025, with a net profit of $-12.6M (-10.6% margin). Cost of goods sold was N/A, operating expenses totaled N/A.
Key Financial Metrics
| Total Revenue | $118.7M |
|---|---|
| Net Profit | $-12.6M |
| Gross Margin | N/A |
| Operating Margin | -12.2% |
| Report Period | Q3 2025 |
Tarsus Pharmaceuticals, Inc. Annual Revenue by Year
Tarsus Pharmaceuticals, Inc. annual revenue history includes year-by-year totals (for example, 2024 revenue was $183.0M).
| Year | Annual Revenue |
|---|---|
| 2024 | $183.0M |
| 2023 | $17.4M |
| 2022 | $25.8M |
Income Statement
| Q4 2023 | Q1 2024 | Q2 2024 | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | |
|---|---|---|---|---|---|---|---|---|
| Revenue | $13.1M | $27.6M | $40.8M | $48.1M | $66.4M | $78.3M | $102.7M | $118.7M |
| YoY Growth | 30.8% | 1004.6% | N/A | 2471.8% | 407.9% | 183.7% | 151.5% | 146.7% |
Balance Sheet
| Q4 2023 | Q1 2024 | Q2 2024 | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | |
|---|---|---|---|---|---|---|---|---|
| Assets | $265.5M | $349.3M | $376.8M | $376.3M | $377.0M | $500.8M | $495.0M | $534.6M |
| Liabilities | $68.5M | $74.1M | $124.6M | $138.8M | $152.5M | $158.3M | $162.4M | $199.5M |
| Equity | $197.0M | $275.2M | $252.2M | $237.5M | $224.5M | $342.5M | $332.6M | $335.1M |
Cash Flow
| Q4 2023 | Q1 2024 | Q2 2024 | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | |
|---|---|---|---|---|---|---|---|---|
| Operating CF | $-39.3M | $-37.8M | $-14.4M | $-8.7M | $-22.2M | $-20.7M | $-29.4M | $18.3M |